Erythropoietin and vascular endothelial growth factor as risk markers for severe hypoglycaemia in type 1 diabetes.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Endocrinology

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/EJE-10-0464PMID 20566589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erythropoietin response to anemia and its association with autonomic neuropathy in type 2 diabetic patients without advanced renal failure.

  2010cited by this paper
• Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance.

  2010cited by this paper
• Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study.

  2009cited by this paper
• Erythropoietin during hypoglycaemia in type 1 diabetes: relation to basal renin-angiotensin system activity and cognitive function.

  2009cited by this paper
• Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity.

  2009cited by this paper
• Erythropoietin Improves Mood and Modulates the Cognitive and Neural Processing of Emotion 3 Days Post Administration

  2008cited by this paper
• Genetic variation and activity of the renin-angiotensin system and severe hypoglycemia in type 1 diabetes.

  2008cited by this paper
• Divergent effects of hyper- and hypoglycemia on circulating vascular endothelial growth factor in humans.

  2008cited by this paper
• Non-hypoxic induction of HIF-3α by 2-deoxy-d-glucose and insulin

  2007cited by this paper
• Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration

  2007cited by this paper
• Non-hypoxic induction of HIF-3alpha by 2-deoxy-D-glucose and insulin.

  2007cited by this paper
• Serum angiotensin‐converting enzyme and frequency of severe hypoglycaemia in Type 1 diabetes: does a relationship exist?

  2007cited by this paper
• Behavior of vascular endothelial growth factor and erythropoietin throughout the menstrual cycle in healthy women.

  2007cited by this paper
• Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus

  2006cited by this paper
• High plasma VEGF relates to low carbohydrate intake in patients with type 2 diabetes

  2006cited by this paper
• The Brain Erythropoietin System and its Potential for Therapeutic Exploitation in Brain Disease

  2006cited by this paper
• Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus

  2006cited by this paper
• Antecedent hypoglycaemia attenuates vascular endothelial growth factor response to subsequent hypoglycaemia in healthy men

  2005cited by this paper
• Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection

  2004cited by this paper
• Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention.

  2004cited by this paper
• Angiotensin II Induces Hypoxia-Inducible Factor-1α in PC 12 Cells through a Posttranscriptional Mechanism: Role of AT2 Receptors

  2004cited by this paper
• Diurnal variations of serum erythropoietin in trained and untrained subjects

  2004cited by this paper
• Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain.

  2003cited by this paper
• Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes.

  2003cited by this paper
• Recall of severe hypoglycaemia and self‐estimated state of awareness in type 1 diabetes

  2003cited by this paper
• Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia.

  2002cited by this paper
• Cellular adaptation to hypoxia: O2‐sensing protein hydroxylases, hypoxia‐inducible transcription factors, and O2‐regulated gene expression

  2002cited by this paper
• The neuroendocrine control of glucose allocation.

  2002cited by this paper
• Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures.

  2002cited by this paper
• Prediction of Severe Hypoglycaemia by Angiotensin-Converting Enzyme Activity and Genotype in Type 1 Diabetes

  2002cited by this paper
• Hypoglycemia-induced VEGF expression is mediated by intracellular Ca2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells.

  2001cited by this paper
• Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain

  2001cited by this paper
• Risk factors for frequent and severe hypoglycemia in type 1 diabetes.

  2001cited by this paper
• Circulating plasma vascular endothelial growth factor and microvascular complications of Type 1 diabetes mellitus: the influence of ACE inhibition

  2001cited by this paper
• Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.

  2001cited by this paper
• Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications

  2000cited by this paper
• Changes in Serum Levels of Vascular Endothelial Growth Factor in Males and Females Throughout Life

  2000cited by this paper
• Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells.

  2000cited by this paper
• Stimulating effect of erythropoietin on the release of dopamine and acetylcholine from the rat brain slice.

  2000cited by this paper
• Up‐regulation of vascular endothelial growth factor in response to glucose deprivation

  1998cited by this paper
• Risk factors of severe hypoglycaemia in adult patients with Type I diabetes – a prospective population based study

  1998cited by this paper
• Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group.

  1997cited by this paper
• The biology of vascular endothelial growth factor.

  1997cited by this paper
• Erythropoietin does not demonstrate circadian rhythm in healthy men.

  1996cited by this paper
• Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA.

  1996cited by this paper
• Direct measurement of brain glucose concentrations in humans by 13C NMR spectroscopy.

  1992cited by this paper
• Symptomatic Hypoglycaemia in 411 Type 1 Diabetic Patients

  1991cited by this paper
• Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin.

  1990cited by this paper
• Effect of erythropoietin on the glucose transport of rat erythrocytes and bone marrow cells.

  1987cited by this paper

• Association of detectable C-peptide levels with glycemic control and chronic complications in individuals with type 1 diabetes mellitus: A systematic review and meta-analysis.

  2024cites this paper
• Normal distribution with plasticizing component

  2020cites this paper
• The polar-generalized normal distribution: properties, Bayesian estimation and applications

  2020cites this paper
• The Recombinant Human Erythropoietin Administered in Neonatal Rats After Excitotoxic Damage Induces Molecular Changes in the Hippocampus

  2019cites this paper
• Bimodal skew-symmetric normal distribution

  2016influential citation
• Erythropoietin and glucose homeostasis in women at varying degrees of future diabetic risk.

  2015cites this paper